Opinion
Video
Author(s):
Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.
Revisit Every OncLive On Air Episode From May 2024
Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
CAR T-Cell Therapy Makes its Mark in CLL
Revisit the OncLive On Air Episodes From February 2024
Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
Pellini Discusses Immunotherapies and Current Limitations of ctDNA in Perioperative NSCLC
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma
Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer
Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC
Dr Hughes on Efficacy Data for Asciminib in Newly Diagnosed Ph+ CP-CML